Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France

Vexiau, P.; Mavros, Panagiotis; Krishnarajah, Girishanthy; Lyu, R.; Yin, Donald

doi:10.1111/j.1463-1326.2008.00883.x

Cited by 96 publications

(71 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…45 An increase in the risk of hypoglycemia is well known with SU therapy and an increase in hypoglycemic events has been reported when these agents are used in combination with other antihyperglycemic drugs, such as metformin and GLP-1 agonists. 46,47 Adjustment of SU therapy to a lower dose should, therefore, be considered when adding linagliptin to pre-existing SU therapy. This is recommended in the prescribing information for linagliptin 9 and other DPP-4 inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

Lehrke

Marx

Patel

et al. 2014

Clinical Therapeutics

View full text Add to dashboard Cite

This updated and expanded pooled, post hoc analysis of 22 placebo-controlled trials of linagliptin 5 mg daily supports previous findings of the acceptable overall safety/tolerability profile of linagliptin when administered to a broad range of patients with T2DM. Linagliptin-treated patients demonstrated a low overall risk of hypoglycemia (risk increased by concomitant sulfonylurea therapy). As with all pooled analyses, this study is limited by the use of data from different studies, and the relatively short duration of some included studies, although use of individual patient data from consistently designed trials should minimize methodological differences between trials. Results from ongoing clinical trials will provide additional insight into the long-term safety/tolerability of linagliptin.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

Lehrke

Marx

Patel

et al. 2014

Clinical Therapeutics

View full text Add to dashboard Cite

show abstract

“…Studies have reported that between 24 and 60 % of patients with diabetes experience NSHEs [3][4][5][6], and symptoms can have a serious impact on a person's quality of life, health, psychological well-being, and adherence to treatment regimens [7]. Quality of life has further been shown to decrease as the frequency and severity of hypoglycemic events increase [4].…”

Section: Introductionmentioning

confidence: 97%

Assessing the impact of non-severe hypoglycemic events and treatment in adults: development of the Treatment-Related Impact Measure—Non-severe Hypoglycemic Events (TRIM-HYPO)

Brod

Højbjerre

Bushnell³

et al. 2015

Qual Life Res

View full text Add to dashboard Cite

show abstract

“…Sulfonylurea use is found to be associated with significantly higher incidence of hypoglycemia than with metformin [32]. Incidence and severity of hypoglycemia is reported to be associated with increased patient anxiety about hypoglycemia and lower health-related quality of life in T2DM patients under metformin and a SU treatment [33]. In comparison with SU, a SGLT2 inhibitor (dapagliflozin) is reported to cause significantly lower incidence of hypoglycemia (7% vs. 29%) [34].…”

Section: Discussionmentioning

confidence: 98%

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis

Shao

Wang

et al. 2018

Endocr J

View full text Add to dashboard Cite

Abstract. This study evaluates the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors as add-on to metformin and sulfonylurea treatment for type 2 diabetes management. The literature search was conducted in electronic databases and meta-analyses of mean differences in the changes from baseline in selected disease endpoints (efficacy endpoints) or odds ratios (for safety endpoints) were performed to compare outcomes between SGLT2 inhibitor-and placebo-/ comparator-treatments. Seven studies (5, There were no significant differences in reduction of either HbA1c, FPG or body weight between 18-24 weeks and after 52-76 weeks of treatment. Treatment with SGLT2 inhibitors as add-on to metformin and sulfonylurea was also associated with significant reductions in blood pressure and triglycerides and increase in high-density lipoprotein-cholesterol. Incidence of hypoglycemia was significantly higher, but incidence of hyperglycemia was significantly lower in SGLT2 inhibitor group. Overall, drug-related adverse events were more common in SGLT2 group mainly due to higher incidence of genital tract infections.

show abstract

Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France

Abstract: The occurrence and severity of hypoglycaemic symptoms were associated with increased patient worry about hypoglycaemia and lower health-related quality of life among type 2 diabetic patients being treated with both metformin and a sulphonylurea.

Cited by 96 publications

References 29 publications

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

Assessing the impact of non-severe hypoglycemic events and treatment in adults: development of the Treatment-Related Impact Measure—Non-severe Hypoglycemic Events (TRIM-HYPO)

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis

Contact Info

Product

Resources

About